$LDOS

Leidos Q3 FY26 slides: strong EPS growth masks revenue headwinds

Leidos Holdings (LDOS) reported Q3 FY26 earnings with EPS up 18.7% YoY to $3.62, but revenue of $4.63B missed estimates. Shares fell 4.62%. Health segment faced challenges, while other segments grew. Operating cash flow declined 26.4%. Management lowered revenue guidance but raised EPS outlook, cautioning no bottom-line growth in FY27.

Original reporting
Published Nov 3, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LDOS
Neutral
high confidence
Mentioned
$LDOS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LDOSNeutralMed
01

Why it matters

The key trade-off is profit momentum versus revenue headwinds. Guidance updates show lower revenue range but higher non-GAAP EPS and improved operating cash flow, while FY27 is explicitly framed as not a bottom-line growth year.

02

Market read

Traders can reassess near-term valuation support from EPS and margin expansion against forward revenue risk and the company’s explicit FY27 caution.

03

What to watch

Health segment VBA recompete progress and the SES joint venture cash-flow uplift may reduce the perceived downside to FY27 if terms remain favorable and integration benefits continue.

Relevance 8/10Novelty 7/10Timing: post-earnings, same-day reaction context (Nov 3, 2026)

Background

Leidos is executing its NorthStar 2030 strategy across Intelligence & Digital, Health, Homeland Security, and Defense, while navigating segment-specific contract changes.

Company-level read

Ticker impact

$LDOSNeutralHigh confidence
Context

Leidos reported Q3 FY26 non-GAAP EPS of $3.62 (+18.7% YoY) but revenue of $4.63B missed expectations and FY27 was flagged as not a bottom-line growth year.

Expected impact

Likely near-term pressure or choppy trading as investors weigh EPS strength against revenue miss and cautious FY27 commentary.

Evidence & confidence

The article pairs a clear EPS beat with explicit revenue underperformance and management guidance caution for FY27, which typically offsets the positive EPS narrative.

Market effects

Defense and government services contractors may see read-through on margin durability versus revenue softness tied to contract recompetes.

Limited, primarily US defense services sentiment.

Low, largely company-specific execution and US federal contracting dynamics.

Counterpoint

EPS strength and improved operating cash flow guidance (plus SES joint venture impact) could outweigh revenue softness if investors focus on margin and cash conversion rather than top-line timing.

Key entities

  • Leidos Holdings

    Defense and government services contractor reporting Q3 FY26 results and updating FY26 guidance with cautious FY27 commentary.

  • NorthStar 2030

    Leidos strategic framework referenced as driving execution across technology and infrastructure initiatives.

  • Veterans Benefits Administration (VBA) disability exam contracts

    Health segment contract changes cited as the main revenue headwind and margin compression driver.

Related articles

$LDOSMed

Leidos expands production capacity to build thousands of cruise missiles for U.S. strike arsenal

Leidos is expanding production capacity to build thousands of cruise missiles for the U.S. under a framework agreement with the Department of War. The company plans to deliver the first weapons in 2027, with full-rate production starting in 2028. Leidos is investing in facilities, supply chain, and workforce to scale production quickly, with work concentrated in Alabama and Tennessee.

$LDOSHighAI 8/10

Leidos stock falls revenue outlook disappoints

Leidos LDOS shares fell 2.1% premarket after Q3 earnings beat estimates but revenue missed expectations, leading to lowered 2026 revenue guidance. Adjusted earnings rose 19% to $3.62, while revenue increased to $4.63B. Health segment revenue declined 12%, offsetting growth in other areas. The company raised its adjusted earnings forecast but reduced revenue outlook, highlighting challenges in translating contract backlog into revenue growth.

$LDOSHighAI 8/10

Leidos raises FY26 adjusted EPS guidance to $12.50-$12.70

Leidos Holdings Inc. raised its FY26 adjusted EPS guidance to $12.50-$12.70 from $12.20-$12.50, citing improved profitability. Sales guidance was lowered to $18.000B-$18.200B from $18.200B-$18.400B due to the SES joint venture. Operating cash flow was increased to ~$1.90B from ~$1.85B. Q2 revenue grew 7% YoY to $4.56B, with record operating cash flow of $793M.